APA (7th ed.) Citation

Sandborn, W. J., Vermeire, S., Tyrrell, H., Hassanali, A., Lacey, S., Tole, S., & Tatro, A. R. (2020). Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program. Advances in therapy, 37(7), 3417-3431. https://doi.org/10.1007/s12325-020-01366-2

Chicago Style (17th ed.) Citation

Sandborn, William J., Severine Vermeire, Helen Tyrrell, Azra Hassanali, Stuart Lacey, Swati Tole, and Amanda R. Tatro. "Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program." Advances in Therapy 37, no. 7 (2020): 3417-3431. https://doi.org/10.1007/s12325-020-01366-2.

MLA (9th ed.) Citation

Sandborn, William J., et al. "Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program." Advances in Therapy, vol. 37, no. 7, 2020, pp. 3417-3431, https://doi.org/10.1007/s12325-020-01366-2.